Evidence map›Paper›PMID 40781926›Full record

ArticleThoracic cancer2025

Sortilin-1, Targeted by miR-146a, Regulates the Behavior of Non-Small Cell Lung Cancer.

Xi Lin, Zhi Yan, Ling Hai, Yan Niu, Jian-Xun Wen, Hong-Zhe Zhu, Cheng Yan, Su-Na Cha, Li Yan, Wen-Qi Zheng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xi LinDepartment of Thoracic Surgery, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Zhi YanDepartment of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Ling HaiDepartment of Pathology, Basic Medical College, Inner Mongolia Medical University, Hohhot, China.
Yan NiuKey Laboratory for Biomarkers, Inner Mongolia Medical University, Hohhot, China.
Jian-Xun WenKey Laboratory for Biomarkers, Inner Mongolia Medical University, Hohhot, China.
Hong-Zhe ZhuDepartment of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Cheng YanDepartment of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Su-Na ChaDepartment of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Li YanKey Laboratory for Biomarkers, Inner Mongolia Medical University, Hohhot, China.
Wen-Qi ZhengDepartment of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.ORCID https://orcid.org/0000-0002-2970-3768
Man ZhangDepartment of Thoracic Surgery, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Zhi-De HuDepartment of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.ORCID https://orcid.org/0000-0003-3679-4992

Funding

Natural Science Foundation of Inner Mongolia Autonomous Region of China 2024MS08055
6 · The paper itself

Abstract

backgroundSortilin-1 (SORT1) has been implicated in the pathogenesis of various malignancies, but its role in non-small cell lung cancer (NSCLC) remains to be elucidated.

methodsImmunohistochemistry was employed to assess the expression of SORT1 in cancerous tissues compared to adjacent non-cancerous tissues. NSCLC cell lines, including A549, H1299, and PC-9, underwent treatment with miR-146a mimics or SORT1 small interfering RNA (siRNA), followed by evaluations of cell viability, migration, invasion, and apoptosis using cell counting kit-8, transwell assays, and scratch wound assays. Additionally, bioinformatic methods were employed to predict miR-146a target genes, which were subsequently validated through dual-luciferase reporter assays.

resultsSORT1 was significantly elevated in NSCLC tissues compared to adjacent non-cancerous counterparts. Downregulation of SORT1 inhibited proliferation, invasion, migration of tumor cell lines and promoted apoptosis. Moreover, SORT1 was a direct target of miR-146a. MiR-146a modulated tumor cell proliferation, migration, invasion, and apoptosis by suppressing SORT1 expression.

conclusionThese results suggest that miR-146a plays a critical role in the pathogenesis of NSCLC by targeting SORT1, highlighting its potential as a therapeutic target for NSCLC.

Indexed as

Adaptor Proteins, Vesicular TransportCarcinoma, Non-Small-Cell LungLung NeoplasmsMicroRNAsApoptosisCell Line, TumorCell MovementCell SurvivalDown-RegulationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm InvasivenessSortilinAdaptor Proteins, Vesicular TransportMicroRNAsMIRN146 microRNA, humanSortilinmiR‐146aNSCLCsortilin‐1

Identifiers

PMID40781926
PMCPMC12334890

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.